BioLargo, Inc. reported a significant decline in financial performance for the third quarter of 2025, with total revenues of $1.1 million, a decrease of 75% compared to $4.4 million in the same period of 2024. For the nine months ending September 30, 2025, revenues totaled $7.1 million, down 49% from $14.1 million in the prior year. The company attributed this decline primarily to reduced sales of its pet odor control product, which was previously marketed under the brand name "Pooph." This product accounted for 35% of total revenue in Q3 2025, down from 74% in Q3 2024. The company also recorded a net loss of $7.2 million for the quarter, compared to a loss of $1.1 million in the same quarter last year.
The financial results reflect a substantial increase in operating expenses, which rose to $7.6 million in Q3 2025 from $2.8 million in Q3 2024. This increase was driven by a $3.8 million credit loss expense related to uncollectible accounts from Pooph, which has been the subject of ongoing litigation. The company’s selling, general, and administrative expenses also increased by 48% year-over-year, largely due to higher salaries and professional fees.
In terms of operational developments, BioLargo's employee headcount stood at 42 as of September 30, 2025. The company continues to focus on its core business segments, including environmental engineering and water treatment technologies. However, it has faced challenges in generating revenue from its Clyra Medical subsidiary, which has not yet commenced commercial sales. The company is actively pursuing partnerships and collaborations to enhance its market presence and product offerings.
Looking ahead, BioLargo expressed concerns regarding its liquidity and capital resources, indicating that gross profits may not be sufficient to sustain operations through the remainder of 2025. The company reported current assets of $5.8 million and current liabilities of $3.5 million as of September 30, 2025, resulting in working capital of $2.3 million. Management anticipates the need for additional investment capital to fund ongoing operations and technology investments, raising substantial doubt about the company's ability to continue as a going concern without increased revenues or financing.
In summary, BioLargo, Inc. is navigating a challenging financial landscape marked by declining revenues and increased losses, primarily due to issues with a key product line and ongoing litigation. The company is focused on strategic partnerships and operational efficiencies to stabilize its financial position while addressing liquidity concerns.
About BIOLARGO, INC.
BioLargo, Inc. develops and commercializes innovative cleantech solutions addressing environmental and health challenges. Its core businesses include industrial and consumer odor and VOC control products, advanced water treatment systems targeting contaminants like PFAS and micropollutants, long-duration battery energy storage technologies, and antimicrobial medical devices. Operating through specialized subsidiaries, BioLargo serves municipal, industrial, and healthcare markets by delivering patented, energy-efficient, and environmentally sustainable technologies supported by engineering services.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.